Madrid, Spain – A new mapping technology developed by Corify Care is poised to revolutionize the diagnosis and treatment of cardiac arrhythmias. The technology, known as Global Volumetric Mapping, offers physicians a comprehensive, real-time view of all four heart chambers simultaneously – a capability previously unavailable with existing methods. This breakthrough promises faster, more accurate assessments and potentially less invasive procedures for patients experiencing irregular heartbeats.
Current electrophysiological mapping systems analyze the heart chamber by chamber, requiring clinicians to infer activity in areas not directly visualized. Corify Care’s innovation overcomes this limitation by mapping the entire heart surface, including electrical activity within the heart walls and septum, in a single beat. This “whole-heart map” reveals how arrhythmias move through the heart, both before and during ablation therapy, providing a level of detail that could significantly improve treatment outcomes.
A New Perspective on Arrhythmia Mapping
The Global Volumetric Mapping technology, detailed in a recent publication in Communications Medicine, allows physicians to visualize arrhythmia pathways often missed by conventional tools. These hidden circuits can be located deep within the heart wall or span multiple chambers, making them difficult to identify and treat. By eliminating these “blind spots,” Corify Care’s system aims to enhance the efficiency and predictability of complex cardiac procedures.
“This is about visibility and confidence,” said Andreu Climent, PhD, CEO of Corify Care. “We give physicians the full picture upfront, not fragments. A global view means faster decisions, more targeted ablations, and potentially less complex and shorter procedures, providing clinical clarity.”
How the Technology Works
Unlike traditional mapping systems that focus on individual chambers, Corify Care’s technology delivers a single-beat, whole-heart map. This allows clinicians to observe how arrhythmias propagate through the heart muscle and across chambers in real-time. Felipe Atienza, MD, PhD, Chief Medical Officer of Corify Care, emphasized the clinical impact, stating, “For the first time, People can non-invasively observe the heart as it truly behaves—globally. That has direct implications for workflow, outcomes, and scalability within EP labs.”
Jorge Vicente-Puig, PhD, lead author of the research, highlighted the importance of a volumetric approach. “Our research demonstrates that a volumetric approach is essential for true arrhythmia characterization. We have moved beyond the mathematical limitations of the past and now offer a fully three-dimensional physiological picture,” he explained.
Regulatory Approval and Future Applications
The ACORYS system from Corify Care has received CE certification for use in Europe and is currently under review by the U.S. Food and Drug Administration (FDA). The company is likewise working on integrating the technology with leading catheter navigation platforms to create a seamless workflow in the electrophysiology (EP) lab. New clinical data on the application of Global Volumetric Mapping in atrial fibrillation and ventricular tachycardia will be presented at the AF Symposium in Boston in February 2026. Corify Care anticipates this will pave the way for broader clinical adoption of whole-heart mapping.
Smartwatches and Early Arrhythmia Detection
The development of Corify Care’s technology coincides with growing interest in the use of consumer wearables for early arrhythmia detection. A recent study conducted by the Amsterdam UMC and Cardiologie Centra Nederland found that smartwatches with integrated heart-monitoring features detected arrhythmias four times more often than traditional monitoring methods in 437 patients at increased risk. Medical Xpress reported that atrial fibrillation, a condition that increases stroke risk, was identified earlier in smartwatch users, often even in the absence of noticeable symptoms. This research underscores the potential of continuous, long-term monitoring for identifying intermittent or asymptomatic arrhythmias.
As cardiac mapping technology advances and consumer wearables become more sophisticated, the future of arrhythmia diagnosis and treatment appears increasingly focused on proactive, personalized care. The combination of detailed anatomical mapping and continuous physiological monitoring promises to improve outcomes and enhance the quality of life for individuals at risk of or living with heart rhythm disturbances.
Disclaimer: This article provides informational content about medical technology and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider for any questions you may have regarding a medical condition.
What are your thoughts on the potential of wearable technology to improve heart health? Share your comments below, and please share this article with your network.
